γ-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 21, Issue 9, 2014, Pages 3084-3089

  Ma, Hui ^a   Zhang, Lan ^a   Tang, Bei ^a   Wang, Yan ^a   Chen, Rongxin ^a   Zhang, Boheng ^a   Chen, Yi ^a   Ge, Ningling ^a   Wang, Yanhong ^a   Gan, Yuhong ^a   Ye, Shenglong ^a   Ren, Zhenggang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GAMMA-GLUTAMYLTRANSFERASE, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR ABLATION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906216224     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3724-4     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:68-90.
2. Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-92.
3. Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, et al. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticanc. 2013;13:469-79.
4. Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79-86.
5. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-89. (Pubitemid 351171044)
6. Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408-25.
7. Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787-93.
8. Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169-82.
9. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314-8. (Pubitemid 38338741)
10. Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102-8.
11. Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, et al. Preoperative serumgamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-42.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
13. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20-5.
14. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72:98-103. (Pubitemid 350256672)
15. Guglielmi A, Ruaaenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, et al. Radiofrequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143-9.
16. Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol. 2012;19:1284-91.
17. Pompella A, Tata VD, Paolicchi A, Zunino F. Expression of γglutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231-8. (Pubitemid 41817283)
18. Hanahan D, Weiberg RA. Hallmarkers of cancer: the next generation. Cell. 2011;144:646-74.
19. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatic C virus-associated cirrhosis and HCC. Cancer. 1997;79:688-94. (Pubitemid 27076334)
20. Everhart JE, Wright EC. Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57:1725-33.